Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

Phase 1TerminatedNCT03417830

GlaxoSmithKline2 enrolled

Overview

The principal aim of this study is to investigate the cardiac uptake of 89Zr-GSK2398852 in subjects with transthyretin cardiomyopathy amyloidosis (ATTR-CM), and its biodistribution to other organs. Low doses of GSK2398852 will be co-administered at levels not high enough for therapeutic benefit. This study will be conducted in two parts: Part A and Part B. Subjects in Part A will participate in up to two dosing sessions and subjects in Part B will participate in one dosing session. Subjects will undergo up to 3 PET scans at varying intervals after 89Zr-GSK2398852 administration. The total duration of study will be approximately 3 to 4 months for subjects in Part A and approximately 2 months for subjects in Part B. Part B of the study will be triggered based on data obtained in Part A and other emerging data.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Amyloidosis

Interventions

Eligibility

Sex: ALLMin age: 65 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must be 65 to 80 years of age inclusive, at the time of signing the informed consent. * Subjects with a diagnosis of ATTR-CM: a) Wild-type ATTR status must be confirmed by genotyping and have one of the following: i) Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarized light in cardiac or other tissue biopsy and identification of Transthyretin amyloidosis (TTR) as the amyloid fibril protein either by immunohistochemistry or proteomic analysis OR ii) Scintigraphy Technetium-99m-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) with confirmed myocardial uptake. b) Hereditary ATTR amyloidosis (example, TTR Val30Met) should have a known amyloidogenic TTR mutation demonstrated by genotyping and is recognized to be primarily associated with cardiomyopathy and one of the following: i) Definite histochemical identification of amyloid by Congo red staining and green birefringence in crossed polarized light in cardiac or other tissue biopsy and identification of TTR as the amyloid fibril protein either by immunohistochemistry or proteomic analysis. ii) Scintigraphy: 99mTc-DPD with confirmed myocardial uptake. * Both male and female subjects are eligible to participate. a) Male subjects: A male subject must agree to use contraception during the treatment period and for at least 3 months after the last scan and refrain from donating sperm during this period. b) Female subjects: A female subject is eligible to participate if she is not of childbearing potential. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol. * New York Heart Association (NYHA) up to class 3; subjects should be clinically stable for at least 3 months preceding to Screening. Exclusion Criteria: * Cardiomyopathy primarily caused by non-amyloid diseases (example, ischemic heart disease; valvular heart disease). * Interval from the Q wave on the ECG to point T using Fredericia's formula (QTcF) \>500 milliseconds (msec). * Sustained (at a rate of \>=120 beats per minute for \>=30 seconds), or symptomatic monomorphic ventricular tachycardia (VT), or rapid polymorphic VT, at Screening/Baseline cardiac monitoring. * Systolic blood pressure \<=100 millimeters of mercury (mm/Hg) based on triplicate readings at Screening. * Unstable heart failure defined as emergency hospitalization for worsening, or decompensated heart failure, or syncopal episode within 1 month of screening. * Implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM) at Screening. * Estimated Glomerular filtration rate (eGFR) at Screening \<50 milliliters per minute (mL/min) calculated using modification of diet in renal disease (MDRD). * Any active and persistent dermatological condition, which in the opinion of the Investigator and Medical Monitor would preclude safe participation. * History of allogeneic stem cell transplantation, prior solid organ transplant, or anticipated to undergo solid organ transplantation, or left ventricular assist device (LVAD) implantation. * Malignancy within last 5 years, except for basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix that has been successfully treated. * Acute coronary syndrome, or any form of coronary revascularization procedure (including coronary artery bypass grafting \[CABG\]), within 6 months of screening. * Symptomatic, clinically significant autonomic neuropathy which the Principal Investigator (PI) feels will preclude administration of study treatment. * Uncontrolled hypertension during Screening. * ALT \>3 times upper limit of normal (ULN) OR bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Peripheral edema at Screening that in the opinion of the PI or designee might prevent adequate absorption of subcutaneously administered CPHPC. * Presence of any co-morbid (example, steroid refractory rheumatoid arthritis), or an uncontrolled medical condition (example, diabetes mellitus), which in the opinion of the investigator would increase the potential risk to the subject. Investigator should liaise with the Medical Monitor where there is uncertainty as to the eligibility of a subject. * Positive test for hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) during Screening, or within 3 months prior to first dose of study treatment. * Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A \[IgA\] dermatosis, toxic epidermal necrolysis and exfoliative dermatitis). * Inability to comprehend and/or understand the study patient information sheet, and/or unwillingness or inability to follow the procedures outlined in the protocol. * Has any of the following: a) Fulfillment of diagnostic criteria for Amyloid Light-chain (AL) amyloidosis. b) Fulfillment of diagnostic criteria for amyloid A (AA) or non-TTR hereditary amyloidosis. * ATTR Disease Load: c) Histologically proven or clinically suspected gastrointestinal TTR amyloidosis; d) Diffuse skeletal muscle uptake of 99m(Tc)-DPD on Single-photon emission computed tomography (SPECT) imaging (where available); e) Peripheral neuropathy causing more than mild morbidity (example, walking disability; neuropathic pain affecting activities of daily living); f) Proven or clinically suspected intracranial TTR involvement including ophthalmological disease. * Non-amyloidosis related chronic liver disease (with the exception of Gilbert's syndrome or clinically asymptomatic gallstones). * Participation in a separate clinical trial involving CPHPC within 3 months of Screening. * Any prohibited concomitant medication within referenced timeframe. * Treatment with another investigational drug, biological agent, or device within 6 months of screening, or 5 half-lives of the study agent, whichever is longer. * Orthopnea of sufficient severity to preclude supine scanning as determined at Screening. * Inability to fit inside scanner due to body size (girth). * History of claustrophobia. * Contraindication to magnetic resonance imaging (MRI) contrast agents. * Contraindication for MRI scanning (as assessed by local MRI safety questionnaire), which includes but is not limited to: a) Intracranial aneurysm clips (except Sugita) or other metallic objects; b) Intra-orbital metal fragments that have not been removed; c) Pacemakers or other implanted cardiac rhythm management/monitoring devices and non-magnetic resonance (MR) conditional heart valves; d) Inner ear implants. * Donation of blood or blood products in excess of 500 milliliters (mL) within 84 days of Screening. * Poor or unsuitable venous access.

Outcomes

Primary Outcomes

Part A- Session 1: Peak Standardized Uptake Values (SUV) in Focal Anatomical Regions of the Heart Following 80-200 mg Dose of Anti-SAP mAb

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for each region of interest such as blood pool left atrium, blood pool left ventricle, blood pool right ventricle, left ventricle wall - high uptake, left ventricle wall - low uptake, mid septum - high uptake and mid septum - low uptake. Peak SUV values derived from PET images has been presented. All treated population consisted of all participants who received at least one Anti-SAP treatment including 89Zr-GSK2398852.

Time frame: Session 1: Days 4, 5, 6 and 8

Part A- Session 2: Peak SUV in Focal Anatomical Regions of the Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg

Time frame: Session 2: Days 3, 4 and 5

Part B: Peak SUV in Focal Anatomical Regions of the Heart Following 80-200 mg Dose of Anti-SAP mAb

SUV in focal anatomical regions of the heart was planned to be measured.

Time frame: Days 3, 4 and 6

Part B: Peak SUV in Focal Anatomical Regions of the Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV in focal anatomical regions of the heart was planned to be measured.

Time frame: Days 3, 4 and 6

Part A- Session 1: Mean SUV of Whole Heart Following 80-200 mg Dose of Anti-SAP mAb

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight.

Time frame: Session 1: Days 4, 5, 6 and 8

Part A- Session 2: Mean SUV of Whole Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight.

Time frame: Session 2: Days 3, 4 and 5

Part B: Mean SUV of Whole Heart Following 80-200 mg Dose of Anti-SAP mAb

SUV of whole heart was planned to be measured.

Time frame: Days 3, 4 and 6

Part B: Mean SUV of Whole Heart Following Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV of whole heart was planned to be measured.

Time frame: Days 3, 4 and 6

Secondary Outcomes

Part A- Session 1: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb

Time frame: Session 1: Days 4, 5, 6 and 8

Part A- Session 1: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Thyriod Gland-goitre Hotspot

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for thyroid gland-goitre hotspot. Mean SUV derived from PET images has been presented.

Time frame: Session 1: Days 4 and 6

Part A- Session 2: Mean SUV of Focal Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for each region of interest such as thyroid gland-goitre hotspot, abdominal skin and skin of the back. Mean SUV derived from PET images has been presented.

Time frame: Session 2: Days 3, 4 and 5

Part B: Mean SUV of Focal Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb

SUV of focal radioactivity uptake for different organs/tissues was planned to be measured.

Time frame: Days 3, 4 and 6

Part B: Mean SUV of Focal Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV of focal radioactivity uptake for different organs/tissues was planned to be measured.

Time frame: Days 3, 4 and 6

Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for each region of interest such as adrenal gland, aorta, bone marrow, kidney, liver, spleen, abdominal region, brain, lung, parotid gland, and thigh. Mean SUV derived from PET images has been presented.

Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Thyroid Gland-goitre

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for thyroid gland-goitre. Mean SUV derived from PET images has been presented.

Time frame: Session 1: Days 4 and 6

Part A- Session 1: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb: Testes

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for testes. Mean SUV derived from PET images has been presented.

Time frame: Session 1: Days 4, 5 and 8

Part A- Session 2: Mean SUV of Total Radioactivity Uptake After Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV was measured radioactivity concentration corrected for radioactive decay and normalized for administered amount of radioactivity per body weight. SUV was analyzed for each region of interest such as adrenal gland, aorta, bone marrow, kidney, liver, spleen, abdominal region, brain, lung, parotid gland, thigh, and thyroid gland- goitre. Mean SUV derived from PET images has been presented.

Time frame: Session 2: Days 3, 4, and 5

Part B: Mean SUV of Total Radioactivity Uptake After 80-200 mg Dose of Anti-SAP mAb

SUV of total radioactivity uptake for different organs/tissues was planned to be measured.

Time frame: Days 3, 4 and 6

Part B: Mean SUV of Total Radioactivity Uptake After an Anti-SAP mAb Dose Between 200 mg and <=500 mg

SUV of total radioactivity uptake for different organs/tissues was planned to be measured.

Time frame: Days 3, 4 and 6

Part A: Maximum Concentration in Plasma (Cmax) of Total mAb

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852). PK Population consisted of all participants from the All Treated Population for whom a PK sample was obtained and analyzed.

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: Cmax of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A: Time Associated With Cmax (Tmax) of Total mAb

Blood samples were collected at indicated time points for PK analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852).

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: Tmax of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A: Clearance of Total mAb

Blood samples were collected at indicated time points for PK analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852).

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: Clearance of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A: Terminal Half-life (T1/2) of Total mAb

Blood samples were collected at indicated time points for PK analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852).

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: T1/2 of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A:Area Under the Concentration Time Curve Till Last Observation (AUC[0 to t]) of Total mAb

Blood samples were collected at indicated time points for PK analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852).

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: AUC(0 to t) of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A: Area Under the Concentration Time Curve Till Time Infinity (AUC[0 to Infinity]) of Total mAb

Blood samples were collected at indicated time points for PK analysis of total mAb (unlabelled GSK2398852 and 89Zr-GSK2398852).

Time frame: Sessions 1 and 2: Day 3 (pre-dose, halfway infusion, end of infusion, 4 and 7 hours after end of infusion), Days 4, 5, 6 and 7

Part B: AUC(0 to Infinity) of Total mAb

Blood samples were planned to be collected at indicated time points for PK analysis of total mAb.

Time frame: Day 3 (pre-dose, end of infusion, 4 and 7 hours post-infusion), Days 4, 5, 6, 7 and 8

Part A: Cmax of 89Zr-GSK2398852 PKs of Radioactivity (Radio-PK)

Blood samples were collected at indicated time points for measurement of radioactivity. Radioactivity reflected the total concentration of 89Zr-GSK2398852 and its radioactive metabolites. Plasma radioactive concentration was measured using scintillation counter.

Time frame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part B: Cmax of 89Zr-GSK2398852 Radio-PK

Blood samples were planned to be collected at indicated time points for measurement of radioactivity. Radioactivity reflected the total concentration of 89Zr-GSK2398852 and its radioactive metabolites. Plasma radioactive concentration was planned to be measured by scintillation counter.

Time frame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part A: Tmax of 89Zr- GSK2398852 Radio-PK

Time frame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part B: Tmax of 89Zr-GSK2398852 Radio-PK

Time frame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part A: T1/2 of 89Zr- GSK2398852 Radio-PK

Time frame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part B: T1/2 of 89Zr- GSK2398852 Radio-PK

Time frame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part A: AUC(0 to t) of 89Zr- GSK2398852 Radio-PK

Time frame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part B: AUC(0 to t) of 89Zr- GSK2398852 Radio-PK

Time frame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part A: AUC(0 to Infinity) of 89Zr- GSK2398852 Radio-PK

Time frame: Sessions 1 and 2: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part B: AUC(0 to Infinity) of 89Zr- GSK2398852 Radio-PK

Time frame: Day 3 (10 minutes, 60 minutes, 4 hours, 7 hours post-dose), Days 4, 5 and 6

Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least one dose of GSK2315698, GSK2398852 or 89Zr-GSK2398852.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With AEs and SAEs

Time frame: Up to Day 26

Part A: Number of Participants With Skin Rashes

Rash was graded as Grade 1 to Grade 4 based on symptoms and body surface area (BSA) affected; Grade 1: \<10 percent (%) BSA and asymptomatic; Grade 2: 10-30% BSA and/or mild symptoms (pain, itch and burning); Grade 3: \>30% BSA and/or moderate/severe symptoms (pain, itch and burning); and Grade 4: any rash with mucosal or systemic involvement (such as evidence of renal involvement).

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Skin Rashes

Rash was planned to be graded as Grade 1 to Grade 4 based on symptoms and BSA affected; Grade 1: \<10% BSA and asymptomatic; Grade 2: 10-30% BSA and/or mild symptoms (pain, itch and burning); Grade 3: \>30% BSA and/or moderate/severe symptoms (pain, itch and burning); and Grade 4: any rash with mucosal or systemic involvement (such as evidence of renal involvement).

Time frame: Up to Day 26

Part A: Number of Participants With Cardiac Adverse Events

The number of participants with any cardiovascular AEs i.e. any AE coded to the cardiovascular system organ class are presented.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Cardiac Adverse Events

The number of participants with any cardiovascular AEs i.e. any AE coded to the cardiovascular system organ class were planned to be reported.

Time frame: Up to Day 26

Part A: Number of Participants With Infusion Related Reactions

Number of participants with any infusion related reactions are presented.

Time frame: Up to Day 26 of the last session

Part A: Change From Baseline in Cardiac Troponin T and N-terminal Prohormone of Brain Natriuretic Peptide (NT-ProBNP)

Blood samples were collected to analyze the troponin T and NT-ProBNP at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 26; Session 2: Day 1- Pre-dose, Days 2, 3, 4, 5, 6, 7, 8, 9, 10 and 26

Part B: Change From Baseline in Cardiac Troponin T and NT-ProBNP

Blood samples were planned to be collected to analyze the troponin T and NT-ProBNP at indicated time points. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Baseline and up to Day 26

Part A: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings

12-lead ECGs were measured in a semi-supine position using an automated ECG machine after approximately 5 minutes of rest for the participant. Abnormal findings were categorized as clinically significant (CS) and not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal 12-lead ECG Findings

12-lead ECGs were planned to be measured in a semi-supine position using an automated ECG machine after approximately 5 minutes of rest for the participant.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Inpatient Cardiac Telemetry

Continuous inpatient cardiac monitoring was performed via remote cardiac telemetry device. Abnormal findings were categorized as CS and NCS. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Inpatient Cardiac Telemetry

Continuous inpatient cardiac monitoring was planned to be performed via remote cardiac telemetry device.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Outpatient Cardiac Telemetry

Continuous outpatient cardiac monitoring was performed via remote cardiac bodyguardian telemetry device. Abnormal findings were categorized as CS and NCS. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Outpatient Cardiac Telemetry

Continuous outpatient cardiac monitoring was planned to be performed via remote cardiac bodyguardian telemetry device.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in a semi-supine position after 5 minutes of rest for the participant. Potential Clinical Importance (PCI) ranges for the SBP and DBP were as follows: SBP- \<90 and \>180 millimeters of mercury (mmHg), and DBP- \<30 and \>110 mmHg.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal SBP and DBP

SBP and DBP were planned to be measured in a semi-supine position after 5 minutes of rest for the participant.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Temperature

Temperature was measured in a semi-supine position after 5 minutes of rest for the participant. Normal range for temperature was as follows: temperature- \>37.5 degree celsius.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Temperature

Temperature was planned to be measured in a semi-supine position after 5 minutes of rest for the participant.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Respiratory Rate

Respiratory rate was measured in a semi-supine position after 5 minutes of rest for the participant. Normal range for the respiratory rate was as follows: respiratory rate- \<12 and \>25 breaths per minute.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Respiratory Rate

Respiratory rate was planned to be measured in a semi-supine position after 5 minutes of rest for the participant.

Time frame: Up to Day 26

Part A: Number of Participants With Abnormal Pulse Rate

Pulse rate were measured in a semi-supine position after 5 minutes of rest for the participant. PCI range for the pulse rate was as follows: pulse rate- \<35 and \>140 beats per minute (bpm).

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Pulse Rate

Pulse rate was planned to be measured in a semi-supine position after 5 minutes of rest for the participant.

Time frame: Up to Day 26

Part A: Number of Participants With New Abnormal Physical Examination Findings

A full and brief physical examination was performed, including assessments of the skin, lungs, cardiovascular system and abdomen (liver and spleen).

Time frame: Session 1: At screening (within 35 days of Anti-SAP treatment of session 1), Day 1 Pre-dose, Day 3, Day 5, Day 8 and Day 11; Session 2: Day 1 Pre-dose, Day 3, Day 5, Day 8 and Day 11

Part B: Number of Participants With New Abnormal Physical Examination Findings

A full and brief physical examination was planned to be performed, including assessments of the skin, lungs, cardiovascular system and abdomen (liver and spleen).

Time frame: At screening (within 35 days of Anti-SAP treatment), Days 1, 3, 5, 8 and 11

Part A: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1-Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets

Blood samples were planned to be collected to analyze the hematology parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze the hematology parameter: Hematocrit. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1-Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were planned to be collected to analyze the hematology parameter.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected to analyze the hematology parameter: Hemoglobin. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were planned to be collected to analyze the hematology parameter.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were planned to be collected to analyze the hematology parameter.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were planned to be collected to analyze the hematology parameter.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes

Blood samples were collected to analyze the hematology parameters: Erythrocytes and Reticulocytes. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Hematology Parameters: Erythrocytes, Reticulocytes

Blood samples were planned to be collected to analyze the hematology parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: Glucose, Calcium, Potassium, Sodium and Urea. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Chemistry Parameters: Glucose, Calcium, Potassium, Sodium, Urea

Blood samples were planned to be collected to analyze the chemistry parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Chemistry Parameters: Albumin, Protein

Blood samples were collected to analyze the chemistry parameters: Albumin and Protein. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Chemistry Parameters: Albumin, Protein

Blood samples were planned to be collected to analyze the chemistry parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST)

Blood samples were collected to analyze the chemistry parameters: ALP, ALT and AST. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Chemistry Parameters: ALP, ALT, AST

Blood samples were planned to be collected to analyze the chemistry parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Change From Baseline in Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine

Blood samples were collected to analyze the chemistry parameters: Direct Bilirubin, Bilirubin, Creatinine. Baseline was considered as the latest pre-dose assessment prior to first administration of either study drug, i.e. GSK2315698 or anti-SAP mAb (labelled or unlabelled) (Day 1, Pre-dose). Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame: Session 1: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26; Session 2: Day 1- Pre-dose, Days 3, 5, 7, 10 and 26

Part B: Change From Baseline in Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine

Blood samples were planned to be collected to analyze the chemistry parameters.

Time frame: Baseline (Day 1 Pre-dose), Days 3, 5, 7, 10 and 26

Part A: Number of Participants With Abnormal Urinalysis Parameters: Glucose, Protein, Blood, Ketones

Urine samples were collected to analyze urinalysis parameters including glucose, protein, blood and ketones.

Time frame: Up to Day 26 of the last session

Part A: Number of Participants With Abnormal Urinalysis Parameters: Specific Gravity, Potential of Hydrogen

Urine samples were collected to analyze urinalysis parameters including specific gravity and potential of hydrogen.

Time frame: Up to Day 26 of the last session

Part B: Number of Participants With Abnormal Urinalysis Parameters: Glucose, Protein, Blood, Ketones

Urine samples were planned to be collected to analyze the urinalysis parameters.

Time frame: Up to Day 26

Part B: Number of Participants With Abnormal Urinalysis Parameters: Specific Gravity, Potential of Hydrogen

Urine samples were planned to be collected to analyze the urinalysis parameters.

Time frame: Up to Day 26

Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes